Gupta Digant, Trukova Kristen, Popiel Brenten, Lammersfeld Carolyn, Vashi Pankaj G
Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, Zion, Illinois, United States of America.
PLoS One. 2015 Mar 16;10(3):e0119690. doi: 10.1371/journal.pone.0119690. eCollection 2015.
BACKGROUND/AIMS: Emerging evidence in the literature suggests a positive association between serum 25-hydroxyvitamin D [25(OH)D], a standard indicator of vitamin D status, and survival in certain types of cancer. We investigated this relationship in newly diagnosed stage IV prostate cancer patients.
A consecutive cohort of 125 newly diagnosed stage IV prostate cancer patients underwent a baseline serum 25(OH)D evaluation prior to receiving any treatment at our institution between January 2008 and December 2011. We used the vitamin D categories of "deficient (<20 ng/ml)", "insufficient (20 to 32 ng/ml)", and "sufficient (>32 ng/ml)". Cox regression was used to evaluate the prognostic significance of serum 25(OH)D after adjusting for relevant confounders.
Mean age at diagnosis was 60 years. Of the 125 patients, 32 (25.6%) were deficient, 49 (39.2%) were insufficient and 44 (35.2%) were sufficient in vitamin D at the time of diagnosis. The median survival in deficient, insufficient and sufficient cohorts was 47.8, 44.0 and 52.6 months respectively (p = 0.60). On univariate analysis, four variables demonstrated a statistically significant association with survival: nutritional status, bone metastasis, corrected serum calcium and serum albumin (p<0.05 for all). On multivariate analysis, five variables demonstrated statistically significant associations with survival: hospital location, age, bone metastasis, serum albumin and corrected serum calcium (p<0.05 for all). Serum vitamin D status was not significant on either univariate or multivariate analysis.
Contrary to previously published research, we found no significant association between pre-treatment serum 25(OH)D and survival in newly diagnosed stage IV prostate cancer patients. The lack of a significant association between serum vitamin D and survival in our study could perhaps be due to the fact that the disease was far too advanced in our patients for vitamin D levels to have any impact on prognosis.
背景/目的:文献中的新证据表明,作为维生素D状态的标准指标,血清25-羟基维生素D[25(OH)D]与某些类型癌症的生存率之间存在正相关。我们在新诊断的IV期前列腺癌患者中研究了这种关系。
2008年1月至2011年12月期间,在我们机构接受治疗前,对连续的125例新诊断的IV期前列腺癌患者进行了基线血清25(OH)D评估。我们使用了“缺乏(<20 ng/ml)”、“不足(20至32 ng/ml)”和“充足(>32 ng/ml)”的维生素D分类。在调整相关混杂因素后,使用Cox回归评估血清25(OH)D的预后意义。
诊断时的平均年龄为60岁。在125例患者中,诊断时维生素D缺乏的有32例(25.6%),不足的有49例(39.2%),充足的有44例(35.2%)。缺乏、不足和充足组的中位生存期分别为47.8、44.0和52.6个月(p = 0.60)。单因素分析显示,有四个变量与生存率有统计学显著关联:营养状况、骨转移、校正血清钙和血清白蛋白(均p<0.05)。多因素分析显示,有五个变量与生存率有统计学显著关联:医院位置、年龄、骨转移、血清白蛋白和校正血清钙(均p<0.05)。血清维生素D状态在单因素或多因素分析中均无显著性。
与先前发表的研究相反,我们发现新诊断的IV期前列腺癌患者治疗前血清25(OH)D与生存率之间无显著关联。我们的研究中血清维生素D与生存率缺乏显著关联,可能是因为我们的患者疾病进展过于严重,以至于维生素D水平对预后没有任何影响。